Gut microbiota, hypertension and chronic kidney disease: Recent advances

被引:57
|
作者
Sircana, Antonio [1 ,3 ]
De Michieli, Franco [2 ,3 ]
Parente, Renato [2 ,3 ]
Framarin, Luciana [2 ,3 ]
Leone, Nicola [2 ,3 ]
Berrutti, Mara [2 ,3 ]
Paschetta, Elena [2 ,3 ]
Bongiovanni, Daria [2 ,3 ]
Musso, Giovanni [2 ,3 ]
机构
[1] Azienda Osped Univ, Unita Operat Cardiol, Sassari, Italy
[2] Univ Turin, HUMANITAS Gradenigo, Turin, Italy
[3] San Giovanni Battista Hosp, Dept Med Sci, Turin, Italy
关键词
Ckd; Blood pressure; Inflammation; TLR-4; GLP-1; Probiotics; CHAIN FATTY-ACIDS; GLUCAGON-LIKE PEPTIDE-1; GLP-1 RECEPTOR AGONISTS; TRIMETHYLAMINE-N-OXIDE; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; SOLUTE P-CRESOL; BLOOD-PRESSURE; METABOLIC SYNDROME; INDOXYL SULFATE;
D O I
10.1016/j.phrs.2018.01.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A large number of different microbial species populates intestine. Extensive research has studied the entire microbial population and their genes (microbiome) by using metagenomics, metatranscriptomics and metabolomic analysis. Studies suggest that the imbalances of the microbial community causes alterations in the intestinal homeostasis, leading to repercussions on other systems: metabolic, nervous, cardiovascular, immune. These studies have also shown that alterations in the structure and function of the gut microbiota play a key role in the pathogenesis and complications of Hypertension (HTN) and Chronic Kidney Disease (CKD). Increased blood pressure (BP) and CKD are two leading risk factors for cardiovascular disease and their treatment represents a challenge for the clinicians. In this Review, we discuss mechanisms whereby gut microbiota (GM) and its metabolites act on downstream cellular targets to contribute to the pathogenesis of HTN and CKD, and potential therapeutic implications. (C) 2018 Published by Elsevier Ltd.
引用
收藏
页码:390 / 408
页数:19
相关论文
共 50 条
  • [1] The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease
    Tao Yang
    Elaine M. Richards
    Carl J. Pepine
    Mohan K. Raizada
    Nature Reviews Nephrology, 2018, 14 : 442 - 456
  • [2] The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease
    Yang, Tao
    Richards, Elaine M.
    Pepine, Carl J.
    Raizada, Mohan K.
    NATURE REVIEWS NEPHROLOGY, 2018, 14 (07) : 442 - 456
  • [3] Gut microbiota in kidney disease and hypertension
    Antza, C.
    Stabouli, S.
    Kotsis, V.
    PHARMACOLOGICAL RESEARCH, 2018, 130 : 198 - 203
  • [4] Recent advances in the management of secondary hypertension: chronic kidney disease
    Masuda, Takahiro
    Nagata, Daisuke
    HYPERTENSION RESEARCH, 2020, 43 (09) : 869 - 875
  • [5] Recent advances in the management of secondary hypertension: chronic kidney disease
    Takahiro Masuda
    Daisuke Nagata
    Hypertension Research, 2020, 43 : 869 - 875
  • [6] Chronic kidney disease and gut microbiota
    Khiabani, Siamak Amini
    Asgharzadeh, Mohammad
    Kafil, Hossein Samadi
    HELIYON, 2023, 9 (08)
  • [7] GUT MICROBIOTA IN CHRONIC KIDNEY DISEASE
    Nalewajska, Magdalena
    Przybycinski, Jaroslaw
    Marchelek-Mysliwiec, Malgorzata
    Dziedziejko, Violetta
    Ciechanowski, Kazimierz
    ADVANCEMENTS OF MICROBIOLOGY, 2019, 58 (03) : 237 - 245
  • [8] Gut microbiota in chronic kidney disease
    Cigarran Guldris, Secundino
    Gonzalez Parra, Emilio
    Cases Amenos, Aleix
    NEFROLOGIA, 2017, 37 (01): : 9 - 19
  • [9] Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease
    Meijers, B.
    Jouret, F.
    Evenepoel, P.
    PHARMACOLOGICAL RESEARCH, 2018, 133 : 101 - 107
  • [10] Homeostasis in the Gut Microbiota in Chronic Kidney Disease
    Bhargava, Shruti
    Merckelbach, Erik
    Noels, Heidi
    Vohra, Ashima
    Jankowski, Joachim
    TOXINS, 2022, 14 (10)